Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,488,399
  • Shares Outstanding, K 169,182
  • Annual Sales, $ 957,800 K
  • Annual Income, $ 226,450 K
  • EBIT $ 94 M
  • EBITDA $ 101 M
  • 60-Month Beta 0.68
  • Price/Sales 4.27
  • Price/Cash Flow 38.11
  • Price/Book 4.95

Options Overview Details

View History
  • Implied Volatility 66.90% (+27.76%)
  • Historical Volatility 25.75%
  • IV Percentile 84%
  • IV Rank 35.05%
  • IV High 127.33% on 04/16/25
  • IV Low 34.30% on 03/19/25
  • Expected Move (DTE 35) 1.99 (7.56%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 49
  • Volume Avg (30-Day) 160
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 7,109
  • Open Int (30-Day) 8,635
  • Expected Range 24.33 to 28.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.13
  • Number of Estimates 11
  • High Estimate 0.21
  • Low Estimate 0.05
  • Prior Year 0.17
  • Growth Rate Est. (year over year) -23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.56 +2.62%
on 01/05/26
28.35 -7.48%
on 12/23/25
-0.57 (-2.13%)
since 12/16/25
3-Month
20.33 +29.02%
on 10/17/25
28.35 -7.48%
on 12/23/25
+5.61 (+27.21%)
since 10/16/25
52-Week
13.40 +95.75%
on 04/09/25
28.35 -7.48%
on 12/23/25
+8.71 (+49.71%)
since 01/16/25

Most Recent Stories

More News
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID ® and ~$700 million for DAYBUE ® - Top-line...

ACAD : 26.04 (-1.85%)
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive...

ACAD : 26.04 (-1.85%)
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

-- DAYBUE STIX provides Rett syndrome patients and caregivers with new flexibility and choice in their treatment with DAYBUE -- DAYBUE and DAYBUE STIX are the only FDA-approved...

ACAD : 26.04 (-1.85%)
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. ...

ACAD : 26.04 (-1.85%)
Acadia: Q3 Earnings Snapshot

Acadia: Q3 Earnings Snapshot

ACAD : 26.04 (-1.85%)
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

- Third quarter total revenues of $278.6 million, up 11% year-over-year - Narrowing and raising high end of NUPLAZID ® net product sales guidance...

ACAD : 26.04 (-1.85%)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference ...

ACAD : 26.04 (-1.85%)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference ...

ACAD : 26.04 (-1.85%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors...

ACAD : 26.04 (-1.85%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are...

ACAD : 26.04 (-1.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 27.56
2nd Resistance Point 27.31
1st Resistance Point 26.92
Last Price 26.04
1st Support Level 26.28
2nd Support Level 26.03
3rd Support Level 25.64

See More

52-Week High 28.35
Last Price 26.04
Fibonacci 61.8% 22.64
Fibonacci 50% 20.88
Fibonacci 38.2% 19.11
52-Week Low 13.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar